Fig. 1: Boxplots showing the biomarkers in MM patients versus controls. | Blood Cancer Journal

Fig. 1: Boxplots showing the biomarkers in MM patients versus controls.

From: Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study

Fig. 1

PPL-ct procoagulant phospholipid dependent clotting time, TFa tissue factor activity, FVIIIa activity of factor VIII, *p < 0.0001

Back to article page